riluzole has been researched along with Disease Exacerbation in 76 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riluzole is the only drug to prolong survival for amyotrophic lateral sclerosis (ALS) and, at a dose of 100 mg, was associated with a 35% reduction in mortality in a clinical trial." | 9.27 | Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. ( Al Khleifat, A; Al-Chalabi, A; Bensimon, G; Fang, T; Jones, A; Leigh, PN; Meurgey, JH, 2018) |
| "Rasagiline, a monoamine oxidase B inhibitor with neuroprotective potential in Parkinson's disease, has shown a disease-modifying effect in the SOD1-Gly93Ala low-expressing mouse model of amyotrophic lateral sclerosis, both alone and in combination with riluzole." | 9.27 | Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. ( Boentert, M; Dorst, J; Dreyhaupt, J; Dupuis, L; Emmer, A; Göricke, B; Grehl, T; Grosskreutz, J; Heneka, MT; Hermann, A; Kassubek, J; Ludolph, AC; Meyer, T; Petri, S; Prudlo, J; Schrank, B; Schuster, J; Weiland, U; Weishaupt, JH; Winkler, AS; Wollebæk Johannesen, S; Zeller, D, 2018) |
| "In a pilot study, lithium treatment slowed progression of amyotrophic lateral sclerosis (ALS)." | 9.14 | Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. ( Aggarwal, SP; Conwit, RA; Cudkowicz, M; Jackson, KE; Kaufman, P; McKinley, J; Pinto, H; Schoenfeld, D; Shefner, J; Simpson, E; Zinman, L, 2010) |
| "Treatment with the neuroprotective drug riluzole has previously been shown to increase the probability of survival in patients with amyotrophic lateral sclerosis." | 9.10 | A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. ( Bejuit, R; Bensimon, G; Delumeau, JC; Lacomblez, L; Meininger, V; Truffinet, P, 2002) |
| "Riluzole is the only disease-modifying drug approved for the treatment of amyotrophic lateral sclerosis (ALS), in which it has been demonstrated to extend survival." | 8.82 | The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. ( Bensimon, G; Doble, A, 2004) |
| "Clenbuterol, a beta-agonist, has plausible mechanisms for treating amyotrophic lateral sclerosis (ALS)." | 8.31 | Clenbuterol Treatment Is Safe and Associated With Slowed Disease Progression in a Small Open-Label Trial in Patients With Amyotrophic Lateral Sclerosis. ( Bedlack, R; Koeberl, DD; Li, X; Lutz, MW, 2023) |
| "Reexamine cost-effectiveness of riluzole in the treatment of amyotrophic lateral sclerosis (ALS) in light of recent advances in disease staging and understanding of stage-specific drug effect." | 7.96 | A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole. ( Katzan, IL; Lapin, BR; Pioro, EP; Thakore, NJ; Udeh, BL, 2020) |
| "Riluzole is the only approved oral drug for amyotrophic lateral sclerosis (ALS)." | 7.91 | Interstitial pneumonia and other adverse events in riluzole-administered amyotrophic lateral sclerosis patients: a retrospective observational study. ( Aoki, M; Inoue-Shibui, A; Izumi, R; Kato, M; Kawauchi, Y; Kobayashi, J; Kuroda, H; Suzuki, N; Takai, Y; Warita, H, 2019) |
| "Riluzole is to date the only treatment that prolongs amyotrophic lateral sclerosis (ALS) survival." | 7.74 | Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy. ( Beghi, E; Fraddosio, A; Guerra, V; Lamberti, P; Lepore, V; Logroscino, G; Palagano, G; Samarelli, V; Serlenga, L; Simone, IL; Zoccolella, S, 2007) |
| "In the wobbler mouse motor neuron disease (MND), we firstly evaluated the effect of riluzole, the only approved drug for amyotrophic lateral sclerosis, and compared it with that of brain-derived neurotrophic factor (BDNF)." | 7.72 | Riluzole slows the progression of neuromuscular dysfunction in the wobbler mouse motor neuron disease. ( Ishiyama, T; Mitsumoto, H; Nakayama, C; Nishibe, H; Okada, R, 2004) |
| "This study reports the results of a long-term economic evaluation of riluzole in the treatment of amyotrophic lateral sclerosis (ALS) versus best supportive care in the United Kingdom." | 7.71 | The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK. ( Malek, M; Tavakoli, M, 2001) |
| " This short report provides an overview of the two drugs that have been approved for ALS treatment and highlights an update on the timeline of drug development, how clinical trials were done, the outcome of these trials, primary endpoint, mechanism of actions, dosing information, administration, side effects, and storage procedures." | 6.61 | Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. ( Jaiswal, MK, 2019) |
| "Riluzole therapy was associated with a survival advantage only for the initial treatment period." | 5.42 | Epidemiology of amyotrophic lateral sclerosis and effect of riluzole on disease course. ( Auff, E; Cetin, H; Erdler, M; Fülöp, G; Füzi, J; Hagmann, M; Koppi, S; Löscher, WN; Neumann, K; Ransmayr, G; Rath, J; Reichardt, B; Weber, J; Zimprich, F, 2015) |
| "Riluzole is the only drug to prolong survival for amyotrophic lateral sclerosis (ALS) and, at a dose of 100 mg, was associated with a 35% reduction in mortality in a clinical trial." | 5.27 | Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. ( Al Khleifat, A; Al-Chalabi, A; Bensimon, G; Fang, T; Jones, A; Leigh, PN; Meurgey, JH, 2018) |
| "Rasagiline, a monoamine oxidase B inhibitor with neuroprotective potential in Parkinson's disease, has shown a disease-modifying effect in the SOD1-Gly93Ala low-expressing mouse model of amyotrophic lateral sclerosis, both alone and in combination with riluzole." | 5.27 | Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. ( Boentert, M; Dorst, J; Dreyhaupt, J; Dupuis, L; Emmer, A; Göricke, B; Grehl, T; Grosskreutz, J; Heneka, MT; Hermann, A; Kassubek, J; Ludolph, AC; Meyer, T; Petri, S; Prudlo, J; Schrank, B; Schuster, J; Weiland, U; Weishaupt, JH; Winkler, AS; Wollebæk Johannesen, S; Zeller, D, 2018) |
| "Our objective was to assess the effects of acetyl-L-carnitine (ALC) with riluzole on disability and mortality of amyotrophic lateral sclerosis (ALS)." | 5.17 | Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. ( Beghi, E; Bella, VL; Bonito, V; Buzzi, P; Caponnetto, C; Chiò, A; Corbo, M; Giannini, F; Inghilleri, M; Logroscino, G; Lorusso, L; Lunetta, C; Mazzini, L; Messina, P; Mora, G; Perini, M; Pupillo, E; Quadrelli, ML; Silani, V; Simone, IL; Tremolizzo, L, 2013) |
| "In a pilot study, lithium treatment slowed progression of amyotrophic lateral sclerosis (ALS)." | 5.14 | Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. ( Aggarwal, SP; Conwit, RA; Cudkowicz, M; Jackson, KE; Kaufman, P; McKinley, J; Pinto, H; Schoenfeld, D; Shefner, J; Simpson, E; Zinman, L, 2010) |
| "Treatment with the neuroprotective drug riluzole has previously been shown to increase the probability of survival in patients with amyotrophic lateral sclerosis." | 5.10 | A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. ( Bejuit, R; Bensimon, G; Delumeau, JC; Lacomblez, L; Meininger, V; Truffinet, P, 2002) |
| "Riluzole is the only disease-modifying drug approved for the treatment of amyotrophic lateral sclerosis (ALS), in which it has been demonstrated to extend survival." | 4.82 | The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. ( Bensimon, G; Doble, A, 2004) |
| "Clenbuterol, a beta-agonist, has plausible mechanisms for treating amyotrophic lateral sclerosis (ALS)." | 4.31 | Clenbuterol Treatment Is Safe and Associated With Slowed Disease Progression in a Small Open-Label Trial in Patients With Amyotrophic Lateral Sclerosis. ( Bedlack, R; Koeberl, DD; Li, X; Lutz, MW, 2023) |
| "Reexamine cost-effectiveness of riluzole in the treatment of amyotrophic lateral sclerosis (ALS) in light of recent advances in disease staging and understanding of stage-specific drug effect." | 3.96 | A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole. ( Katzan, IL; Lapin, BR; Pioro, EP; Thakore, NJ; Udeh, BL, 2020) |
| "Riluzole is the only approved oral drug for amyotrophic lateral sclerosis (ALS)." | 3.91 | Interstitial pneumonia and other adverse events in riluzole-administered amyotrophic lateral sclerosis patients: a retrospective observational study. ( Aoki, M; Inoue-Shibui, A; Izumi, R; Kato, M; Kawauchi, Y; Kobayashi, J; Kuroda, H; Suzuki, N; Takai, Y; Warita, H, 2019) |
| "Riluzole is the most widespread therapeutic for treatment of the progressive degenerative disease amyotrophic lateral sclerosis (ALS)." | 3.88 | Riluzole does not improve lifespan or motor function in three ALS mouse models. ( Coughlan, KS; Halang, L; Hogg, MC; Prehn, JHM; Woods, I, 2018) |
| "Riluzole is to date the only treatment that prolongs amyotrophic lateral sclerosis (ALS) survival." | 3.74 | Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy. ( Beghi, E; Fraddosio, A; Guerra, V; Lamberti, P; Lepore, V; Logroscino, G; Palagano, G; Samarelli, V; Serlenga, L; Simone, IL; Zoccolella, S, 2007) |
| "Patients with amyotrophic lateral sclerosis (ALS) who are treated with the antiglutamatergic drug riluzole receive a fixed-dose regimen of 50 mg b." | 3.74 | An association study of riluzole serum concentration and survival and disease progression in patients with ALS. ( Groeneveld, GJ; Guchelaar, HJ; Lie-A-Huen, L; van den Berg, LH; van Kan, HJ, 2008) |
| "In the wobbler mouse motor neuron disease (MND), we firstly evaluated the effect of riluzole, the only approved drug for amyotrophic lateral sclerosis, and compared it with that of brain-derived neurotrophic factor (BDNF)." | 3.72 | Riluzole slows the progression of neuromuscular dysfunction in the wobbler mouse motor neuron disease. ( Ishiyama, T; Mitsumoto, H; Nakayama, C; Nishibe, H; Okada, R, 2004) |
| "This study reports the results of a long-term economic evaluation of riluzole in the treatment of amyotrophic lateral sclerosis (ALS) versus best supportive care in the United Kingdom." | 3.71 | The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK. ( Malek, M; Tavakoli, M, 2001) |
| " The aim of this study was to develop a protocol to determine the proper dosage of Mecasin." | 2.87 | Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial. ( Kang, HW; Kim, D; Kim, JK; Kim, S; Lee, J; Son, I; Son, MJ; Song, B, 2018) |
| "It is hoped that therapeutics in primary progressive multiple sclerosis will continue to expand and effective therapeutic agents will be developed." | 2.71 | Interferon beta-1a in primary progressive multiple sclerosis. ( Leary, SM; Thompson, AJ, 2003) |
| "Riluzole has been established as the only, although modestly effective, disease modifying therapy, extending mean patient survival by 3to 6 months." | 2.61 | Amyotrophic Lateral Sclerosis: Autoimmune Pathogenic Mechanisms, Clinical Features, and Therapeutic Perspectives. ( Artico, M; de Vincentiis, M; Greco, A; Lambiase, A; Ralli, M, 2019) |
| " This short report provides an overview of the two drugs that have been approved for ALS treatment and highlights an update on the timeline of drug development, how clinical trials were done, the outcome of these trials, primary endpoint, mechanism of actions, dosing information, administration, side effects, and storage procedures." | 2.61 | Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. ( Jaiswal, MK, 2019) |
| "Treatment with riluzole improves survival but has a marginal effect on the rate of functional deterioration, whereas non-invasive ventilation prolongs survival and improves or maintains quality of life." | 2.44 | Clinical care of patients with amyotrophic lateral sclerosis. ( Leigh, PN; Mitsumoto, H; Radunović, A, 2007) |
| "However, an objective measure of disease progression and therapeutic response is sorely needed." | 2.40 | Biological markers in the diagnosis and treatment of ALS. ( Arnold, DL; Cashman, NR; Kalra, S, 1999) |
| "Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease resulting in muscle weakness, dysarthria and dysphagia, and ultimately respiratory failure leading to death." | 1.48 | Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis. ( Benstead, T; Briemberg, H; Genge, A; Grant, I; Hader, W; Hodgkinson, VL; Johnston, WS; Kalra, S; Korngut, L; Linassi, G; Lounsberry, J; Massie, R; Melanson, M; Mirian, A; O'Connell, C; Schellenberg, K; Shoesmith, C; Taylor, S; Worley, S; Zinman, L, 2018) |
| "Riluzole treatment was started in 78-85% of cases." | 1.43 | Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. ( Birks, C; Duong, T; Edis, R; Henderson, R; Kiernan, M; Macdonnell, R; Mathers, S; McCombe, P; Needham, M; Rowe, D; Schultz, D; Talman, P; Venkatesh, S; Vucic, S, 2016) |
| "Riluzole therapy was associated with a survival advantage only for the initial treatment period." | 1.42 | Epidemiology of amyotrophic lateral sclerosis and effect of riluzole on disease course. ( Auff, E; Cetin, H; Erdler, M; Fülöp, G; Füzi, J; Hagmann, M; Koppi, S; Löscher, WN; Neumann, K; Ransmayr, G; Rath, J; Reichardt, B; Weber, J; Zimprich, F, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (7.89) | 18.2507 |
| 2000's | 22 (28.95) | 29.6817 |
| 2010's | 35 (46.05) | 24.3611 |
| 2020's | 13 (17.11) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, T | 1 |
| Wei, Q | 1 |
| Li, C | 1 |
| Cao, B | 1 |
| Ou, R | 1 |
| Hou, Y | 1 |
| Zhang, L | 1 |
| Gu, X | 1 |
| Liu, K | 1 |
| Lin, J | 1 |
| Cheng, Y | 1 |
| Jiang, Z | 1 |
| Yang, J | 1 |
| Kang, S | 1 |
| Zhang, M | 1 |
| Xiao, Y | 1 |
| Zhao, B | 2 |
| Chen, Y | 1 |
| Chen, X | 1 |
| Shang, H | 1 |
| Johnson, SA | 1 |
| Fang, T | 2 |
| De Marchi, F | 1 |
| Neel, D | 1 |
| Van Weehaeghe, D | 1 |
| Berry, JD | 1 |
| Paganoni, S | 1 |
| Li, X | 1 |
| Koeberl, DD | 1 |
| Lutz, MW | 1 |
| Bedlack, R | 1 |
| Tzeplaeff, L | 1 |
| Wilfling, S | 1 |
| Requardt, MV | 1 |
| Herdick, M | 1 |
| Lombardo, FL | 1 |
| Spila Alegiani, S | 1 |
| Mayer, F | 1 |
| Cipriani, M | 1 |
| Lo Giudice, M | 1 |
| Ludolph, AC | 2 |
| McDermott, CJ | 1 |
| Corcia, P | 1 |
| Van Damme, P | 1 |
| Van den Berg, LH | 4 |
| Hardiman, O | 1 |
| Nicolini, G | 1 |
| Vanacore, N | 1 |
| Dickie, B | 1 |
| Albanese, A | 1 |
| Puopolo, M | 1 |
| Ralli, M | 1 |
| Lambiase, A | 1 |
| Artico, M | 1 |
| de Vincentiis, M | 1 |
| Greco, A | 1 |
| Loveland, P | 1 |
| Wong, A | 1 |
| Vivekanandam, V | 1 |
| Lim, WK | 1 |
| Kacem, I | 1 |
| Sghaier, I | 1 |
| Bougatef, S | 1 |
| Nasri, A | 1 |
| Gargouri, A | 1 |
| Ajroud-Driss, S | 1 |
| Gouider, R | 1 |
| Chataway, J | 2 |
| De Angelis, F | 1 |
| Connick, P | 1 |
| Parker, RA | 2 |
| Plantone, D | 2 |
| Doshi, A | 2 |
| John, N | 1 |
| Stutters, J | 2 |
| MacManus, D | 2 |
| Prados Carrasco, F | 1 |
| Barkhof, F | 2 |
| Ourselin, S | 1 |
| Braisher, M | 1 |
| Ross, M | 1 |
| Cranswick, G | 1 |
| Pavitt, SH | 1 |
| Giovannoni, G | 3 |
| Gandini Wheeler-Kingshott, CA | 1 |
| Hawkins, C | 1 |
| Sharrack, B | 1 |
| Bastow, R | 1 |
| Weir, CJ | 2 |
| Stallard, N | 1 |
| Chandran, S | 1 |
| Aydemir, D | 1 |
| Ulusu, NN | 1 |
| Meng, H | 2 |
| Wang, Y | 1 |
| Barp, A | 1 |
| Gerardi, F | 1 |
| Lizio, A | 1 |
| Sansone, VA | 1 |
| Lunetta, C | 2 |
| Solanky, BS | 1 |
| John, NA | 1 |
| DeAngelis, F | 1 |
| Prados, F | 1 |
| Schneider, T | 1 |
| Monteverdi, A | 1 |
| Marshall, I | 1 |
| Gandini Wheeler-Kingshott, CAM | 1 |
| Thakore, NJ | 1 |
| Pioro, EP | 1 |
| Udeh, BL | 1 |
| Lapin, BR | 1 |
| Katzan, IL | 1 |
| Xu, X | 1 |
| Shen, D | 1 |
| Gao, Y | 1 |
| Zhou, Q | 1 |
| Ni, Y | 1 |
| Shi, H | 1 |
| Le, W | 1 |
| Chen, S | 2 |
| Ilieva, H | 1 |
| Maragakis, NJ | 1 |
| Scott, A | 1 |
| Hogg, MC | 1 |
| Halang, L | 1 |
| Woods, I | 1 |
| Coughlan, KS | 1 |
| Prehn, JHM | 1 |
| Al Khleifat, A | 1 |
| Meurgey, JH | 1 |
| Jones, A | 1 |
| Leigh, PN | 5 |
| Bensimon, G | 5 |
| Al-Chalabi, A | 3 |
| Kim, S | 2 |
| Kim, JK | 1 |
| Son, MJ | 1 |
| Kim, D | 1 |
| Song, B | 1 |
| Son, I | 1 |
| Kang, HW | 1 |
| Lee, J | 1 |
| Schuster, J | 1 |
| Dorst, J | 1 |
| Dupuis, L | 1 |
| Dreyhaupt, J | 1 |
| Weishaupt, JH | 1 |
| Kassubek, J | 1 |
| Weiland, U | 1 |
| Petri, S | 1 |
| Meyer, T | 1 |
| Grosskreutz, J | 1 |
| Schrank, B | 1 |
| Boentert, M | 1 |
| Emmer, A | 1 |
| Hermann, A | 1 |
| Zeller, D | 1 |
| Prudlo, J | 1 |
| Winkler, AS | 1 |
| Grehl, T | 1 |
| Heneka, MT | 1 |
| Wollebæk Johannesen, S | 1 |
| Göricke, B | 1 |
| Jaiswal, MK | 1 |
| Hodgkinson, VL | 1 |
| Lounsberry, J | 1 |
| Mirian, A | 1 |
| Genge, A | 1 |
| Benstead, T | 1 |
| Briemberg, H | 1 |
| Grant, I | 1 |
| Hader, W | 1 |
| Johnston, WS | 1 |
| Kalra, S | 2 |
| Linassi, G | 1 |
| Massie, R | 1 |
| Melanson, M | 1 |
| O'Connell, C | 1 |
| Schellenberg, K | 1 |
| Shoesmith, C | 1 |
| Taylor, S | 1 |
| Worley, S | 1 |
| Zinman, L | 2 |
| Korngut, L | 1 |
| de Jongh, AD | 1 |
| van Eijk, RPA | 1 |
| Klockgether, T | 1 |
| Mariotti, C | 1 |
| Paulson, HL | 1 |
| Inoue-Shibui, A | 1 |
| Kato, M | 1 |
| Suzuki, N | 1 |
| Kobayashi, J | 1 |
| Takai, Y | 1 |
| Izumi, R | 1 |
| Kawauchi, Y | 1 |
| Kuroda, H | 1 |
| Warita, H | 1 |
| Aoki, M | 1 |
| Beghi, E | 2 |
| Pupillo, E | 1 |
| Bonito, V | 1 |
| Buzzi, P | 1 |
| Caponnetto, C | 1 |
| Chiò, A | 1 |
| Corbo, M | 1 |
| Giannini, F | 1 |
| Inghilleri, M | 1 |
| Bella, VL | 1 |
| Logroscino, G | 2 |
| Lorusso, L | 1 |
| Mazzini, L | 1 |
| Messina, P | 1 |
| Mora, G | 1 |
| Perini, M | 1 |
| Quadrelli, ML | 1 |
| Silani, V | 1 |
| Simone, IL | 2 |
| Tremolizzo, L | 1 |
| Li, J | 1 |
| Sung, M | 1 |
| Rutkove, SB | 1 |
| Clavelou, P | 1 |
| Blanquet, M | 1 |
| Peyrol, F | 1 |
| Ouchchane, L | 1 |
| Gerbaud, L | 1 |
| Halpin, L | 1 |
| Savulescu, J | 1 |
| Talbot, K | 1 |
| Turner, M | 2 |
| Talman, P | 2 |
| Pandya, RS | 1 |
| Zhu, H | 1 |
| Li, W | 1 |
| Bowser, R | 2 |
| Friedlander, RM | 1 |
| Wang, X | 1 |
| Puentes, F | 1 |
| Topping, J | 1 |
| Kuhle, J | 2 |
| van der Star, BJ | 1 |
| Douiri, A | 1 |
| Baker, D | 1 |
| Amor, S | 1 |
| Malaspina, A | 1 |
| Cetin, H | 2 |
| Rath, J | 2 |
| Füzi, J | 2 |
| Reichardt, B | 2 |
| Fülöp, G | 1 |
| Koppi, S | 1 |
| Erdler, M | 1 |
| Ransmayr, G | 1 |
| Weber, J | 1 |
| Neumann, K | 1 |
| Hagmann, M | 2 |
| Löscher, WN | 2 |
| Auff, E | 2 |
| Zimprich, F | 2 |
| Bucchia, M | 1 |
| Ramirez, A | 1 |
| Parente, V | 1 |
| Simone, C | 1 |
| Nizzardo, M | 1 |
| Magri, F | 1 |
| Dametti, S | 1 |
| Corti, S | 1 |
| Klickovic, U | 1 |
| Zulehner, G | 1 |
| Wanschitz, J | 1 |
| Shamshiri, H | 2 |
| Fatehi, F | 2 |
| Davoudi, F | 1 |
| Mir, E | 1 |
| Pourmirza, B | 1 |
| Abolfazli, R | 2 |
| Etemadifar, M | 1 |
| Harirchian, MH | 2 |
| Gharagozli, K | 1 |
| Ayromlou, H | 1 |
| Basiri, K | 1 |
| Zamani, B | 2 |
| Rohani, M | 1 |
| Sedighi, B | 2 |
| Roudbari, A | 2 |
| Delavar Kasmaei, H | 1 |
| Nikkhah, K | 1 |
| Ranjbar Naeini, A | 1 |
| Nafissi, S | 2 |
| Moura, MC | 1 |
| Novaes, MR | 1 |
| Eduardo, EJ | 1 |
| Zago, YS | 1 |
| Freitas, Rdel N | 1 |
| Casulari, LA | 1 |
| Nourbakhsh, B | 3 |
| Nunan-Saah, J | 1 |
| Maghzi, AH | 2 |
| Julian, LJ | 1 |
| Spain, R | 2 |
| Jin, C | 1 |
| Lazar, A | 1 |
| Pelletier, D | 3 |
| Waubant, E | 3 |
| Azevedo, C | 1 |
| Knibb, JA | 1 |
| Keren, N | 1 |
| Kulka, A | 1 |
| Martin, S | 1 |
| Shaw, CE | 1 |
| Tsuda, M | 1 |
| Razazian, N | 1 |
| Khamseh, F | 1 |
| Duong, T | 1 |
| Vucic, S | 1 |
| Mathers, S | 1 |
| Venkatesh, S | 1 |
| Henderson, R | 1 |
| Rowe, D | 1 |
| Schultz, D | 1 |
| Edis, R | 1 |
| Needham, M | 1 |
| Macdonnell, R | 1 |
| McCombe, P | 1 |
| Birks, C | 1 |
| Kiernan, M | 3 |
| Moore, A | 1 |
| Young, CA | 1 |
| Hughes, DA | 1 |
| Grant, D | 1 |
| Morant, S | 1 |
| Barro, C | 1 |
| Yaldizli, Ö | 1 |
| Gnanapavan, S | 1 |
| Hoffman, JJ | 1 |
| Ludolph, A | 1 |
| Agid, Y | 1 |
| Vidailhet, M | 1 |
| Payan, C | 1 |
| Andrews, J | 1 |
| Aggarwal, SP | 1 |
| Simpson, E | 1 |
| McKinley, J | 1 |
| Jackson, KE | 1 |
| Pinto, H | 1 |
| Kaufman, P | 1 |
| Conwit, RA | 1 |
| Schoenfeld, D | 1 |
| Shefner, J | 1 |
| Cudkowicz, M | 1 |
| Levine, TD | 1 |
| Hank, N | 1 |
| Saperstein, D | 1 |
| Zoing, M | 1 |
| Wadman, RI | 1 |
| Bosboom, WM | 1 |
| van der Pol, WL | 1 |
| Wokke, JH | 1 |
| Iannaccone, ST | 1 |
| Vrancken, AF | 1 |
| Armon, C | 1 |
| Leary, SM | 1 |
| Thompson, AJ | 1 |
| Cepeda, C | 1 |
| Hurst, RS | 1 |
| Calvert, CR | 1 |
| Hernández-Echeagaray, E | 1 |
| Nguyen, OK | 1 |
| Jocoy, E | 1 |
| Christian, LJ | 1 |
| Ariano, MA | 1 |
| Levine, MS | 1 |
| Dunlop, J | 1 |
| Beal McIlvain, H | 1 |
| She, Y | 1 |
| Howland, DS | 1 |
| Kaufmann, P | 1 |
| Lomen-Hoerth, C | 1 |
| Haddad, H | 1 |
| Cifuentes-Diaz, C | 1 |
| Miroglio, A | 1 |
| Roblot, N | 1 |
| Joshi, V | 1 |
| Melki, J | 1 |
| Ishiyama, T | 1 |
| Okada, R | 1 |
| Nishibe, H | 1 |
| Mitsumoto, H | 2 |
| Nakayama, C | 1 |
| Doble, A | 2 |
| Lundblad, M | 1 |
| Usiello, A | 1 |
| Carta, M | 1 |
| Håkansson, K | 1 |
| Fisone, G | 1 |
| Cenci, MA | 1 |
| Mackenzie, R | 1 |
| McKenzie, D | 1 |
| Youl, BD | 1 |
| Zoccolella, S | 1 |
| Palagano, G | 1 |
| Fraddosio, A | 1 |
| Guerra, V | 1 |
| Samarelli, V | 1 |
| Lepore, V | 1 |
| Lamberti, P | 1 |
| Serlenga, L | 1 |
| Radunović, A | 1 |
| Groeneveld, GJ | 1 |
| van Kan, HJ | 1 |
| Lie-A-Huen, L | 1 |
| Guchelaar, HJ | 1 |
| Andreadou, E | 1 |
| Kapaki, E | 1 |
| Kokotis, P | 1 |
| Paraskevas, GP | 1 |
| Katsaros, N | 1 |
| Libitaki, G | 1 |
| Zis, V | 1 |
| Sfagos, C | 1 |
| Vassilopoulos, D | 1 |
| Gurney, ME | 1 |
| Cutting, FB | 1 |
| Zhai, P | 1 |
| Taylor, CP | 1 |
| Andrus, PK | 1 |
| Hall, ED | 1 |
| Dengler, R | 1 |
| Tröger, M | 1 |
| Arnold, DL | 1 |
| Cashman, NR | 1 |
| Brooks, BR | 1 |
| Jokelainen, M | 1 |
| Turner, MR | 1 |
| Parton, MJ | 1 |
| Tavakoli, M | 1 |
| Malek, M | 1 |
| Borasio, GD | 1 |
| Lacomblez, L | 1 |
| Delumeau, JC | 1 |
| Bejuit, R | 1 |
| Truffinet, P | 1 |
| Meininger, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of the Combined Treatment of Curcumin and Resveratrol Liposomed Polyphenols With G04CB02 on the Clinical Improvement of ALS Patients[NCT04654689] | Phase 2 | 90 participants (Actual) | Interventional | 2021-11-20 | Completed | ||
| A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.[NCT01910259] | Phase 2 | 445 participants (Actual) | Interventional | 2014-12-18 | Completed | ||
| A Multicenter Phase I/II Clinical Trial, Randomized, Controlled With Placebo, Triple Blind to Evaluate Safety, and Indications of Efficiency of the Intravenous Administration of the Therapy With 3 Doses of MSC in Patients With ASL Moderated to Severe[NCT02290886] | Phase 1/Phase 2 | 52 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole) - An AMG Trial With a Market Authorized Substance[NCT01879241] | Phase 2 | 252 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| A Patient Centric Motor Neuron Disease Activities of Daily Living Scale[NCT02852278] | 410 participants (Actual) | Observational | 2016-12-31 | Completed | |||
| Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) in a Representative Iranian Population[NCT03272802] | Phase 2/Phase 3 | 20 participants (Anticipated) | Interventional | 2017-03-16 | Active, not recruiting | ||
| Neuroprotection With Riluzole in Patients With Early Multiple Sclerosis[NCT00501943] | Phase 2 | 43 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Obesity as a Driver of Inflammation and Brain Volume Loss in Pediatric Multiple Sclerosis.[NCT04593082] | 116 participants (Anticipated) | Observational | 2021-06-03 | Recruiting | |||
| A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy[NCT02422485] | Phase 1 | 10 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes)[NCT00211224] | Phase 3 | 800 participants | Interventional | 2000-04-30 | Terminated | ||
| A 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy[NCT02460731] | Phase 1 | 6 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies[NCT01056965] | Phase 1 | 12 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticoba[NCT02133846] | Phase 1 | 44 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| A Multicenter, Double-Blind, Placebo-Controlled, Study to Investigate the Safety and Efficacy of Lithium in Combination With Riluzole in Volunteers With Amyotrophic Lateral Sclerosis (ALS)[NCT00818389] | Phase 2/Phase 3 | 84 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to NINDS DSMB recommended trial be terminated for futility after reviewing an interim analysis of 84 subjects.) | ||
| Initiation of Long-term Home Non-invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Using the iVAPS Mode During a Daytime Trial[NCT01746381] | 30 participants (Actual) | Interventional | 2014-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Baseline MSFC data is compared to MSFC data collected during the timepoints. The MSFC is a three-part, standardized, quantitative, assessment instrument that measures the clinical dimensions of leg function, arm/hand function and cognitive function and the components include Timed 25-Foot walk, 9-Hole Peg Test and Paced Auditory Serial Addition Test. (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24
| Intervention | percent change per year (Mean) |
|---|---|
| Riluzole | 0.041 |
| Placebo | 0.052 |
The baseline data of grey matter volume obtained from the MRI images is compared to data obtained at time points using SIENA (Structural Image Evaluation using Normalization of Atrophy) and SIENAX (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12 and Month-24
| Intervention | percent change per year (Mean) |
|---|---|
| Riluzole | -14.369 |
| Placebo | -18.444 |
The baseline data of white matter volume obtained from the MRI images is compared to data obtained at time points using SIENA (Structural Image Evaluation using Normalization of Atrophy) and SIENAX (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24
| Intervention | percent change per year (Mean) |
|---|---|
| Riluzole | -1.75 |
| Placebo | -9.69 |
Baseline RNFL data is compared to the RNFL data collected during the timepoint, and the changes in RNFL is measured using optical coherence tomography (OCT). (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24
| Intervention | percent change per year (Mean) |
|---|---|
| Riluzole | -4.670 |
| Placebo | -1.839 |
Baseline SDMT data were compared to SDMT data collected during the timepoints. A simple substitution task, the SDMT gives the examinee 90 seconds to pair specific numbers with given geometric figures as a measure for screening cognitive impairment. The total score is the total number of correctly completed boxes in the time allowed. The test score range is from 0(worst outcome) to 110 (best outcome). (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24
| Intervention | percent change per year (Mean) |
|---|---|
| Riluzole | 0.342 |
| Placebo | 0.417 |
Baseline MRI is compared to MRI images collected during subsequent timepoints. The percent brain volume change is measured using SIENAX (Structural Image Evaluation using Normalization of Atrophy-X) (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24
| Intervention | percent change per year (Mean) |
|---|---|
| Riluzole | -0.862 |
| Placebo | -0.49 |
ALSFRS-R is a self-administered ordinal rating scale questionnaire (rating 0-4 for each question,4 is most functional,0-48 total)of 12 functional activities. The most functional total score is 48. ALSFRS-R done at baseline and weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 & 52, dependent on enrollment duration. Number of subjects who failed by treatment group was evaluated. Failure was defined as 6-point drop in ALSFRS-R or death from baseline. (NCT00818389)
Timeframe: 9 months: Baseline to study termination (January 2009 - October 2009)
| Intervention | Participants (Number) |
|---|---|
| Lithium + Riluzole | 18 |
| Placebo + Riluzole | 14 |
ALSFRS-R is a self-administered ordinal rating scale questionnaire (rating 0-4 for each question,4 is most functional,0-48 total)of 12 functional activities. The most functional total score is 48. ALSFRS-R done at baseline and weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 & 52, dependent on enrollment duration. Secondary efficacy was evaluated by comparing the mean rate of decline of ALSFRS-R score by treatment group. (NCT00818389)
Timeframe: 9 months: Baseline to study termination (January 2009 - October 2009)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Lithium + Riluzole | -1.24 |
| Placebo + Riluzole | -1.09 |
Secondary efficacy was measured by comparing the rate of decline of mean VC by treatment group. (NCT00818389)
Timeframe: 9 months: Baseline to study termination (January 2009- October 2009)
| Intervention | Percent of predicted normal (Mean) |
|---|---|
| Lithium + Riluzole | -1.89 |
| Placebo + Riluzole | -3.12 |
21 reviews available for riluzole and Disease Exacerbation
| Article | Year |
|---|---|
Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents.
Topics: Amyotrophic Lateral Sclerosis; Biological Products; Clinical Trials as Topic; Disease Progression; E | 2022 |
Current State and Future Directions in the Therapy of ALS.
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Disease Progression; Humans; Motor Neurons; Riluzole | 2023 |
Amyotrophic Lateral Sclerosis: Autoimmune Pathogenic Mechanisms, Clinical Features, and Therapeutic Perspectives.
Topics: Age Factors; Aged; Amyotrophic Lateral Sclerosis; Diagnosis, Differential; Disease Progression; Fema | 2019 |
Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Progression; Drug Development; Drug Discovery; Edara | 2020 |
A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
Topics: Amyotrophic Lateral Sclerosis; Clinical Trials as Topic; Disease Management; Disease Progression; Ed | 2021 |
Motoneuron Disease: Clinical.
Topics: Amyotrophic Lateral Sclerosis; Disease Progression; Exercise Therapy; Frontotemporal Dementia; Genet | 2017 |
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antioxidants; Clinical Trials as Topic; Disease Models, Anim | 2019 |
Spinocerebellar ataxia.
Topics: Age Factors; Disease Progression; Humans; Mass Screening; Neuroprotective Agents; Postural Balance; | 2019 |
Therapeutic neuroprotective agents for amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Disease M | 2013 |
Therapeutic development in amyotrophic lateral sclerosis.
Topics: Adult; Amyotrophic Lateral Sclerosis; Disease Progression; Humans; Riluzole; Treatment Outcome | 2015 |
Economic Studies in Motor Neurone Disease: A Systematic Methodological Review.
Topics: Costs and Cost Analysis; Disease Progression; Humans; Markov Chains; Models, Economic; Motor Neuron | 2017 |
Toward a better understanding of amyotrophic lateral sclerosis.
Topics: Adult; Advance Care Planning; Amyotrophic Lateral Sclerosis; Community Health Nursing; Disease Progr | 2008 |
Drug treatment for spinal muscular atrophy type I.
Topics: Child, Preschool; Disease Progression; Humans; Infant; Neuroprotective Agents; Randomized Controlled | 2012 |
How can physicians and their patients with ALS decide to use the newly-available treatments to slow disease progression?
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Anticonvulsants; Clinical Trials as Topic; Cyclohex | 1999 |
The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis.
Topics: Aged; Amyotrophic Lateral Sclerosis; Asthenia; Biotransformation; Chemical and Drug Induced Liver In | 2004 |
Clinical care of patients with amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Deglutition Disorders; Disease Progression; Humans; Neuroprotective A | 2007 |
Impact of riluzole on the relationship between patient and physician.
Topics: Amyotrophic Lateral Sclerosis; Attitude; Disease Progression; Emotions; Humans; Neuroprotective Agen | 1997 |
Biological markers in the diagnosis and treatment of ALS.
Topics: Amyotrophic Lateral Sclerosis; Aspartic Acid; Biomarkers; Brain; Creatine; Disease Progression; Elec | 1999 |
What are the implications of early diagnosis? Maintaining optimal health as long as possible.
Topics: Amyotrophic Lateral Sclerosis; Disease Progression; Humans; Neuroprotective Agents; Riluzole | 1999 |
[Pharmacotherapy of amyotrophic lateral sclerosis].
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Anti-Anxiety Agents; Disease Progression; Female; Humans | 1997 |
Clinical trials in ALS: an overview.
Topics: Amyotrophic Lateral Sclerosis; Disease Progression; Excitatory Amino Acid Antagonists; Humans; Meta- | 2001 |
14 trials available for riluzole and Disease Exacerbation
| Article | Year |
|---|---|
A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial.
Topics: Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Humans; Neuroprotective Age | 2023 |
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Topics: Administration, Oral; Adult; Amiloride; Brain; Disease Progression; Double-Blind Method; Female; Flu | 2020 |
NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study.
Topics: Adult; Amiloride; Aspartic Acid; Biomarkers; Child, Preschool; Cohort Studies; Cross-Sectional Studi | 2020 |
Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study.
Topics: Amyotrophic Lateral Sclerosis; Disease Progression; Dose-Response Relationship, Drug; Excitatory Ami | 2018 |
Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Anti-Inflammatory Agents; Clinical Tr | 2018 |
Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Topics: Aged; Amyotrophic Lateral Sclerosis; Body Mass Index; Disease Progression; Double-Blind Method; Fema | 2018 |
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.
Topics: Acetylcarnitine; Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Metho | 2013 |
Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis.
Topics: Adjuvants, Immunologic; Adult; Atrophy; Brain; Cross-Sectional Studies; Disability Evaluation; Disea | 2016 |
Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
Topics: Adjuvants, Immunologic; Adult; Atrophy; Biomarkers; Brain; Disability Evaluation; Disease Progressio | 2017 |
Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
Topics: Adjuvants, Immunologic; Adult; Atrophy; Biomarkers; Brain; Disability Evaluation; Disease Progressio | 2017 |
Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
Topics: Adjuvants, Immunologic; Adult; Atrophy; Biomarkers; Brain; Disability Evaluation; Disease Progressio | 2017 |
Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
Topics: Adjuvants, Immunologic; Adult; Atrophy; Biomarkers; Brain; Disability Evaluation; Disease Progressio | 2017 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Therapy, | 2010 |
A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers.
Topics: Amyotrophic Lateral Sclerosis; Animals; Biomarkers; Disease Progression; Excitatory Amino Acid Antag | 2010 |
Interferon beta-1a in primary progressive multiple sclerosis.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Agents; Disability Evaluation; Disease Pro | 2003 |
A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis.
Topics: Age Factors; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Tol | 2002 |
41 other studies available for riluzole and Disease Exacerbation
| Article | Year |
|---|---|
Spatial-temporal pattern of propagation in amyotrophic lateral sclerosis and effect on survival: A cohort study.
Topics: Amyotrophic Lateral Sclerosis; Cohort Studies; Delayed Diagnosis; Disease Progression; Humans; Progn | 2022 |
Clenbuterol Treatment Is Safe and Associated With Slowed Disease Progression in a Small Open-Label Trial in Patients With Amyotrophic Lateral Sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Clenbuterol; Disease Progression; Female; Hand Strength; Humans; Male | 2023 |
Subacute combined degeneration of the spinal cord masking motor neuron disease: a case report.
Topics: Comorbidity; Confusion; Diagnosis, Differential; Disease Progression; Dysarthria; Electromyography; | 2019 |
Epidemiological and clinical features of amyotrophic lateral sclerosis in a Tunisian cohort.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Cohort Studies; Delayed Diagnosis; Disease Progression; | 2020 |
Importance of the serum biochemical parameters as potential biomarkers for rapid diagnosis and evaluating preclinical stage of ALS.
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Disease Progression; Humans; Prognosis; Riluzole | 2020 |
FOXM1-induced upregulation of lncRNA OR3A4 promotes the progression of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway.
Topics: Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease Progression; Forkhead Box P | 2020 |
A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole.
Topics: Amyotrophic Lateral Sclerosis; Cost-Benefit Analysis; Disease Progression; Drug Costs; Health Care C | 2020 |
Drug therapy: On the treatment trail for ALS.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Benzamides; C9orf72 Protein; Clinical Trials as Topic; Di | 2017 |
Riluzole does not improve lifespan or motor function in three ALS mouse models.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Disease Progression; DNA-Binding Pro | 2018 |
Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Excitatory Amino Acid Antagonists; | 2018 |
Evidence for a multimodal effect of riluzole in patients with ALS?
Topics: Amyotrophic Lateral Sclerosis; Disease Progression; Humans; Neuroprotective Agents; Proportional Haz | 2019 |
Interstitial pneumonia and other adverse events in riluzole-administered amyotrophic lateral sclerosis patients: a retrospective observational study.
Topics: Adult; Amyotrophic Lateral Sclerosis; Chemical and Drug Induced Liver Injury; Disease Progression; F | 2019 |
Electrophysiologic biomarkers for assessing disease progression and the effect of riluzole in SOD1 G93A ALS mice.
Topics: Amino Acid Substitution; Amyotrophic Lateral Sclerosis; Animals; Biomarkers; Disease Models, Animal; | 2013 |
Rates of progression of weight and forced vital capacity as relevant measurement to adapt amyotrophic lateral sclerosis management for patient Result of a French multicentre cohort survey.
Topics: Aged; Amyotrophic Lateral Sclerosis; Body Mass Index; Body Weight; Cohort Studies; Disease Progressi | 2013 |
Improving access to medicines: empowering patients in the quest to improve treatment for rare lethal diseases.
Topics: Amyotrophic Lateral Sclerosis; Compassionate Use Trials; Disease Progression; Drug Approval; Drug In | 2015 |
Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis.
Topics: Aged; Amyotrophic Lateral Sclerosis; Antibodies; Biomarkers; Case-Control Studies; Disease Progressi | 2014 |
Epidemiology of amyotrophic lateral sclerosis and effect of riluzole on disease course.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Austria; Databases, Fact | 2015 |
Associations between co-medications and survival in ALS-a cohort study from Austria.
Topics: Aged; Amyotrophic Lateral Sclerosis; Austria; Cohort Studies; Databases, Factual; Disease Progressio | 2015 |
Amyotrophic lateral sclerosis progression: Iran-ALS clinical registry, a multicentre study.
Topics: Adult; Amyotrophic Lateral Sclerosis; Bulbar Palsy, Progressive; Disease Progression; Extremities; F | 2015 |
Prognostic Factors in Amyotrophic Lateral Sclerosis: A Population-Based Study.
Topics: Adult; Age Factors; Age of Onset; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Body Mass | 2015 |
Longitudinal associations between MRI and cognitive changes in very early MS.
Topics: Adult; Cognition Disorders; Disease Progression; Female; Humans; Longitudinal Studies; Magnetic Reso | 2016 |
A clinical tool for predicting survival in ALS.
Topics: Age Factors; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; England; Female; Humans; Kapl | 2016 |
Trends of quality of life changes in amyotrophic lateral sclerosis patients.
Topics: Age Factors; Amyotrophic Lateral Sclerosis; Disability Evaluation; Disease Progression; Female; Foll | 2016 |
Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort.
Topics: Amyotrophic Lateral Sclerosis; Australia; Disease Progression; Female; Gastrostomy; Humans; Kaplan-M | 2016 |
Amyotrophic lateral sclerosis: clinical management and research update.
Topics: Amyotrophic Lateral Sclerosis; Animals; Clinical Trials as Topic; Disease Progression; Humans; Neuro | 2009 |
Motor neurone disease - caring for the patient in general practice.
Topics: Australia; Deglutition Disorders; Disease Progression; Electrophysiology; General Practice; Humans; | 2011 |
Survival endpoint: pro.
Topics: Amyotrophic Lateral Sclerosis; Disease Progression; Endpoint Determination; Humans; Neuroprotective | 2002 |
Early symptom progression rate is related to ALS outcome: a prospective population-based study.
Topics: Amyotrophic Lateral Sclerosis; Animals; Databases, Factual; Disease Progression; Humans; Neuroprotec | 2002 |
Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease.
Topics: Animals; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Disease Progression; Electrophysi | 2003 |
Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis.
Topics: Amino Acid Transport System X-AG; Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modif | 2003 |
ALS treatment strikes out while trying for a homer: the topiramate trial.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Progression; Drug Evaluation, Preclinical; Fructose; | 2003 |
Riluzole attenuates spinal muscular atrophy disease progression in a mouse model.
Topics: Animals; Axons; Cyclic AMP Response Element-Binding Protein; Cytoskeleton; Disease Progression; Gene | 2003 |
Riluzole slows the progression of neuromuscular dysfunction in the wobbler mouse motor neuron disease.
Topics: Animals; Disease Progression; Female; Mice; Mice, Neurologic Mutants; Motor Neuron Disease; Neuromus | 2004 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal | 2005 |
Hyperimmune goat serum for amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anti-Inflammatory Agents; Antibodies; Disease Progression; G | 2006 |
Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy.
Topics: Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Bulbar | 2007 |
An association study of riluzole serum concentration and survival and disease progression in patients with ALS.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Area Under Curve; Bayes Theorem; Disease Progression; Do | 2008 |
Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment.
Topics: Aged; Amyotrophic Lateral Sclerosis; Chromatography, High Pressure Liquid; Disease Progression; Fema | 2008 |
Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis.
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Animals; Brain; Cyclohexanecarboxylic Acids; Diet; | 1996 |
The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK.
Topics: Amyotrophic Lateral Sclerosis; Cost-Benefit Analysis; Disease Progression; Drug Costs; Forecasting; | 2001 |
Riluzole treatment in advanced ALS.
Topics: Amyotrophic Lateral Sclerosis; Disease Progression; Humans; Medical Futility; Neuroprotective Agents | 2002 |